Publikationen, an denen er mitarbeitet Vicente Soriano Vázquez (56)

2011

  1. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Núm. 4, pp. 457-477

  2. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 18, Núm. 5, pp. 325-330

2010

  1. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 3, pp. 543-547

  2. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection

    Journal of Infectious Diseases, Vol. 202, Núm. 8, pp. 1185-1191

  3. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 4, pp. 1647-1649

  4. Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

    HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204

  5. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244

  6. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 8, pp. 1567-1569

2009

  1. Differences in lopinavir plasma concentrations comparing Kaletra® film coated tablets and soft gelatine capsules that result in various lipid abnormalities

    Drug Metabolism Letters, Vol. 3, Núm. 2, pp. 67-69

  2. Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients

    Clinical Infectious Diseases, Vol. 49, Núm. 9, pp. 1397-1401

  3. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 10, pp. 4153-4158

2008

  1. Association between tipranavir plasma levels and virological response in HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 24, Núm. 3, pp. 389-391

  2. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir

    Clinical Infectious Diseases, Vol. 46, Núm. 11, pp. 1782-1785

  3. Research Letters Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

    AIDS, Vol. 22, Núm. 18, pp. 2535-2537

  4. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring

    AIDS Research and Human Retroviruses, Vol. 24, Núm. 6, pp. 821-825

  5. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 816-822

  6. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 6, pp. 1174-1180

2007

  1. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 7, pp. 879-885

  2. Drug interactions of tipranavir, a new HIV protease inhibitor.

    Drug metabolism letters, Vol. 1, Núm. 1, pp. 81-84

  3. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241